Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
PHILADELPHIA, Jan. 03, 2017 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Jeffrey D. Marrazzo, chief executive officer, is presenting at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, at 11:30 a.m. PST, at the Westin St. Francis Hotel, in San Francisco, California.
A webcast of Marrazzo’s presentation will be available live on www.sparktx.com on the "Events" section of the Investors page. A replay of the presentation will be available on the website for 90 days following the conference. To access his full presentation slide deck, please visit "Investor Presentations" on the Investors page.
In addition, Dan Faga, chief business officer, will participate in a panel discussion on “The coming of age of gene therapy and gene editing,” during the Biotech Showcase on Tuesday, Jan. 10, from 8-9 a.m. PST, at the Hilton San Francisco Union Square.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001, in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer (which also has received both breakthrough therapy and orphan product designations) and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Spark Therapeutics Corporate Contacts: Stephen W. Webster Chief Financial Officer Daniel Faga Chief Business Officer (855) SPARKTX (1-855-772-7589) Media Contact: Dan Quinn Ten Bridge Communication (781) 475-7974 [email protected]
